Company research
IONIS PHARMACEUTICALS INC
CIK 874015Updated Sep 24, 2026
SecurityIONS · NASDAQ · equity
Name history
ISIS PHARMACEUTICALS INC · through Dec 18, 2015
IONS price & chart
Loading TradingView…
NASDAQ:IONS on TradingView ↗About the company
For more than three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.
In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS ↗
Recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
S-8 filing
10-Q filing
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
144 filing
144 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 3,523,836,000Source | 3,003,675,000Source | 2,990,072,000Source | 2,533,876,000Source |
| Property, Plant and Equipment, NetUSD | 123,048,000Source | 94,251,000Source | 71,043,000Source | 74,294,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 372,260,000Source | 242,077,000Source | 399,266,000Source | 276,472,000Source |
| Inventory, NetUSD | 10,048,000Source | 12,512,000Source | 28,425,000Source | 22,033,000Source |
| Assets, CurrentUSD | 2,990,635,000Source | 2,620,290,000Source | 2,641,853,000Source | 2,202,694,000Source |
| Operating Lease, Right-of-Use AssetUSD | 238,549,000Source | 161,856,000Source | 171,896,000Source | 181,544,000Source |
| Other Assets, NoncurrentUSD | 171,604,000Source | 127,278,000Source | 105,280,000Source | 75,344,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 3,034,747,000Source | 2,415,324,000Source | 2,603,386,000Source | 1,960,989,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 163,000Source | 158,000Source | 144,000Source | 142,000Source |
| Retained Earnings (Accumulated Deficit)USD | -2,631,195,000Source | -2,249,808,000Source | -1,795,911,000Source | -1,429,625,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -25,281,000Source | -30,811,000Source | -32,645,000Source | -57,480,000Source |
| Stockholders' Equity Attributable to ParentUSD | 489,089,000Source | 588,351,000Source | 386,686,000Source | 572,887,000Source |
| Additional Paid in Capital, Common StockUSD | 3,145,402,000Source | 2,868,812,000Source | 2,215,098,000Source | 2,059,850,000Source |
| Liabilities and EquityUSD | 3,523,836,000Source | 3,003,675,000Source | 2,990,072,000Source | 2,533,876,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 781,567,000Source | 309,318,000Source | 448,090,000Source | 311,561,000Source |
| Operating Lease, Liability, CurrentUSD | 9,509,000Source | 9,064,000Source | 8,094,000Source | 7,215,000Source |
| Accounts Payable, CurrentUSD | 28,082,000Source | 42,964,000Source | 26,027,000Source | 17,921,000Source |
| Operating Lease, Liability, NoncurrentUSD | 262,383,000Source | 161,805,000Source | 170,875,000Source | 178,941,000Source |
| Other Liabilities, NoncurrentUSD | — | — | — | 7,126,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 106,089,000Source | 108,438,000Source | 147,894,000Source | 140,101,000Source |
| Long-term Debt, Excluding Current Maturities | — | — | — | — |
| Long-term Debt, Current MaturitiesUSD | 432,120,000Source | 165,000Source | 157,000Source | 151,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 1,327,999,000Source | 1,202,405,000Source | 1,241,004,000Source | 1,175,725,000Source |
| Short-term InvestmentsUSD | 2,305,176,000Source | 2,055,579,000Source | 1,931,935,000Source | 1,710,397,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -269,722,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 133,874,000Source | 130,200,000Source | 105,809,000Source | 100,264,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | 13,674,000Source | 5,071,000Source | 6,392,000Source | -2,773,000Source |
| Increase (Decrease) in Accounts PayableUSD | -15,360,000Source | 15,990,000Source | 8,119,000Source | 1,094,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -268,583,000Source | -500,947,000Source | -307,513,000Source | -274,370,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -277,776,000Source | -134,027,000Source | -214,127,000Source | -262,636,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 51,444,000Source | 45,280,000Source | 23,805,000Source | 15,721,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | 0Source | 0Source | 10,953,000Source |
| Payments for Repurchase of Common StockUSD | — | — | — | 0Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 675,840,000Source | 478,058,000Source | 644,082,000Source | -55,295,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 130,183,000Source | -157,189,000Source | 122,794,000Source | -592,719,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 372,260,000Source | 242,077,000Source | 399,266,000Source | 276,472,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 10,782,000Source | 10,869,000Source | 6,512,000Source | 2,898,000Source |
| Income Taxes Paid, NetUSD | -639,000Source | -5,620,000Source | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 133,874,000Source | 130,200,000Source | 105,809,000Source | 100,264,000Source |
| Amortization of Debt Issuance CostsUSD | 6,908,000Source | 6,690,000Source | 6,330,000Source | 5,373,000Source |
| Amortization of Intangible AssetsUSD | 2,439,000Source | 2,336,000Source | 2,559,000Source | 2,415,000Source |
| DepreciationUSD | 10,008,000Source | 9,614,000Source | 10,292,000Source | 14,328,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | 3,991,000Source | -7,404,000Source | -16,649,000Source | -531,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | -12,000Source | -161,000Source | 149,604,000Source |
| Gain (Loss) on InvestmentsUSD | 10,220,000Source | -2,889,000Source | -1,914,000Source | -7,333,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | 0Source | 0Source | 13,389,000Source | 0Source |
| Impairment of Intangible Assets, Finite-livedUSD | 986,000Source | 3,032,000Source | 1,661,000Source | 2,030,000Source |
| Income Tax Expense (Benefit)USD | 1,786,000Source | -6,171,000Source | 32,321,000Source | 11,737,000Source |
| Induced Conversion of Convertible Debt ExpenseUSD | 16,344,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -381,387,000Source | -453,897,000Source | -366,286,000Source | -269,722,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | 0Source |
| Operating Lease, ExpenseUSD | 26,000,000Source | 23,200,000Source | 23,100,000Source | 8,300,000Source |
| Other Nonoperating Income (Expense)USD | -15,358,000Source | 1,343,000Source | 14,256,000Source | -7,274,000Source |
| Proceeds from Issuance of Common StockUSD | 0Source | 489,120,000Source | — | — |
| Realized Investment Gains (Losses)USD | 9,280,000Source | -2,892,000Source | -1,589,000Source | -224,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | 135,664,000Source | 130,999,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 943,711,000Source | 705,138,000Source | 787,647,000Source | 587,367,000Source |
| Cost of RevenueUSD | 15,909,000Source | 11,215,000Source | 9,133,000Source | 14,116,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 393,867,000Source | 267,474,000Source | 232,619,000Source | 150,295,000Source |
| Operating Income (Loss)USD | -381,684,000Source | -475,081,000Source | -353,730,000Source | -410,191,000Source |
| Other Nonoperating Income (Expense)USD | -15,358,000Source | 1,343,000Source | 14,256,000Source | -7,274,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -379,601,000Source | -460,068,000Source | -333,965,000Source | -257,985,000Source |
| Income Tax Expense (Benefit)USD | 1,786,000Source | -6,171,000Source | 32,321,000Source | 11,737,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -381,387,000Source | -453,897,000Source | -366,286,000Source | -269,722,000Source |
| Earnings Per Share, BasicUSD per share | -2.38Source | -3.04Source | -2.56Source | -1.9Source |
| Earnings Per Share, DilutedUSD per share | -2.38Source | -3.04Source | -2.56Source | -1.9Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 160,010,000Source | 149,514,000Source | 143,190,000Source | 141,848,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 160,010,000Source | 149,514,000Source | 143,190,000Source | 141,848,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 2,439,000Source | 2,336,000Source | 2,559,000Source | 2,415,000Source |
| Costs and ExpensesUSD | 1,325,395,000Source | 1,180,219,000Source | 1,141,377,000Source | 997,558,000Source |
| Current Income Tax Expense (Benefit)USD | 1,786,000Source | -6,171,000Source | 32,321,000Source | 11,737,000Source |
| Gain (Loss) on InvestmentsUSD | 10,220,000Source | -2,889,000Source | -1,914,000Source | -7,333,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -381,180,000Source | -460,712,000Source | -334,707,000Source | -258,493,000Source |
| Interest ExpenseUSD | 17,262,000Source | 16,994,000Source | 12,660,000Source | 8,122,000Source |
| Investment Income, NetUSD | 97,765,000Source | 107,022,000Source | 89,041,000Source | 25,331,000Source |
| Operating Lease, ExpenseUSD | 26,000,000Source | 23,200,000Source | 23,100,000Source | 8,300,000Source |
| Realized Investment Gains (Losses)USD | 9,280,000Source | -2,892,000Source | -1,589,000Source | -224,000Source |
| Research and Development ExpenseUSD | 915,619,000Source | — | — | — |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | 135,664,000Source | 130,999,000Source | — | — |
Filing attachments
ef20082626_ex99-1.htm · 8-K · 2026-09-23
Exhibit 99.1 Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN) - Sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential - - IgAN is a progressive kidney disease that is typically diagnosed in young adults and up to 50% of people progress to kidney failure within 20 years, requiring dialysis or transplantation - - Interim d…
Read attachment ↗ef20081690_ex99-1.htm · 8-K · 2026-09-04
EX-99.1 2 ef20081690_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) CARLSBAD, Calif., September 4, 2026 -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Novartis today announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing the risk of cardiovas…
Read attachment ↗ef20081649_ex99-1.htm · 8-K · 2026-09-04
EX-99.1 2 ef20081649_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients - Provides a clinically meaningful impact on motor function and a favorable impact on other symptoms seen in AxD, an ultra-rare, progressive and often fatal neurological disorder - - Priority Review Voucher (PRV) awarded in conjunction with approval - - ZANVASTRO marks Ionis’ fi…
Read attachment ↗ef20078953_ex99-1.htm · 8-K · 2026-07-29
EX-99.1 2 ef20078953_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Ionis reports second quarter 2026 financial results and highlights progress on key programs - TRYNGOLZA® (olezarsen) demonstrating early sHTG launch momentum, underscoring multi-billion-dollar revenue potential in large patient population - - Completed enrollment in Phase 3 REVEAL trial in Angelman syndrome - - On track to achieve 2026 financial guidance - CARLSBAD, Calif., July 29, 2026 - Ionis Pharmaceuticals, Inc. (Nasdaq: ION…
Read attachment ↗ef20077664_ex99-1.htm · 8-K · 2026-07-09
EX-99.1 2 ef20077664_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy - Study missed primary endpoint of composite outcome of cardiovascular (CV) mortality and recurrent CV events; in a pre-specified subgroup analysis, a nominally significant result was observed with eplontersen monotherapy - - Favorable safety profile consistent with previous results - CARLSBAD, Calif., July 9, 2026…
Read attachment ↗ef20076807_ex99-1.htm · 8-K · 2026-06-24
EX-99.1 2 ef20076807_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG) - Proven to deliver significant and robust triglyceride reductions - - Only treatment for sHTG indicated to reduce the risk of acute pancreatitis - - Ionis’ first independent commercial launch in a prevalent condition - - Ionis to host webcast tod…
Read attachment ↗